Successful early use of anti-SARS-CoV-2 monoclonal neutralizing
antibodies in SARS-CoV-2 infected hematological patients - A
Czech multicenter experience

J 2022

Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience

WEINBERGEROVÁ, Barbora, Ivo DEMEL, Benjamin VISEK, Jan VALKA, Martin CERNAN et. al.

Základní údaje

Originální název

Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience

Autoři

WEINBERGEROVÁ, Barbora (203 Česká republika, garant, domácí), Ivo DEMEL (203 Česká republika), Benjamin VISEK (203 Česká republika), Jan VALKA (203 Česká republika), Martin CERNAN (203 Česká republika), Pavel JINDRA (203 Česká republika), Jan NOVAK (203 Česká republika), Lukas STEJSKAL (203 Česká republika), Flóra KOVÁCSOVÁ (703 Slovensko, domácí), Tomáš KABUT (203 Česká republika, domácí), Tomas SZOTKOWSKI (203 Česká republika), Roman HAJEK (203 Česká republika), Pavel ZAK (203 Česká republika), Petr CETKOVSKY (203 Česká republika), Zdeněk KRÁL (203 Česká republika, domácí) a Jiří MAYER (203 Česká republika, domácí)

Vydání

Hematological Oncology, MALDEN, USA, WILEY-BLACKWELL, 2022, 0278-0232

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.300

Kód RIV

RIV/00216224:14110/22:00125823

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/hon.2974

UT WoS

000756686100001

Klíčová slova anglicky

anti-SARS-CoV-2 monoclonal neutralizing antibodies; bamlanivimab; casirivimab; COVID-19; hematological malignancy; imdevimab; SARS-CoV-2

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 5. 2022 13:59, Mgr. Tereza Miškechová

Anotace

V originále

COVID-19 significantly impairs survival rates among hematological patients when compared to the general population. Our prospective multicentre project analyzed early administration of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies (NmAbs) - bamlanivimab (72%) and casirivimab/imdevimab (28%) - efficacy among hematological patients with early-stage COVID-19. Mortality rate was compared to a control cohort of 575 SARS-CoV-2 positive hematological patients untreated with any specific anti-COVID-19 therapy. 88 hematological patients with lymphomas, acute leukemias, and myeloma as their most frequent underlying diagnoses (72%) were evaluated with a 97 days median follow-up after NmAb administration. One third of patients (32%) were treated with an anti-CD20 monoclonal antibody before COVID-19 diagnosis. Median time between first COVID-19 symptom and NmAb administration was 2 days. When administering NmAb, 29%, 57%, 11%, 2%, and 1% of our patients had asymptomatic, mild, moderate, severe, and critical degrees of COVID-19, respectively. 80% of baseline asymptomatic patients remained asymptomatic following NmAb administration. Median duration of COVID-19 symptoms after NmAb administration was 2.5 days. Progression to severe/critical COVID-19 occurred among a total of 17% (15/88) of our cases and numerically higher with bamlanivimab versus casirivimab/imdevimab (21% vs. 8%; p = 0.215), and myelomas (29%), lymphomas (17%) and acute leukemias (18%), respectively. During final follow-up, nine deaths (10%) were recorded - all after bamlanivimab (p = 0.056) with 8% attributed to COVID-19. Regarding "remdesivir/convalescent plasma naive" patients, COVID-19 mortality rates were significantly lower in our NmAbs treated cohort compared to the control cohort of untreated SARS-CoV-2 positive hematological patients (6% vs. 16%, p = 0.020), respectively. Our study validated the safety and efficacy of NmAbs early use among hematological patients with newly diagnosed early-stage COVID-19 in terms of alleviating infection course and decreasing mortality. Results confirmed a more positive effect of a casirivimab/imdevimab combination versus bamlanivimab monotherapy.

Citovat

WEINBERGEROVÁ, Barbora, Ivo DEMEL, Benjamin VISEK, Jan VALKA, Martin CERNAN, Pavel JINDRA, Jan NOVAK, Lukas STEJSKAL, Flóra KOVÁCSOVÁ, Tomáš KABUT, Tomas SZOTKOWSKI, Roman HAJEK, Pavel ZAK, Petr CETKOVSKY, Zdeněk KRÁL a Jiří MAYER. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience. Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2022, roč. 40, č. 2, s. 280-286. ISSN 0278-0232. Dostupné z: https://dx.doi.org/10.1002/hon.2974.

@article{1853633,
   author = {Weinbergerová, Barbora and Demel, Ivo and Visek, Benjamin and Valka, Jan and Cernan, Martin and Jindra, Pavel and Novak, Jan and Stejskal, Lukas and Kovácsová, Flóra and Kabut, Tomáš and Szotkowski, Tomas and Hajek, Roman and Zak, Pavel and Cetkovsky, Petr and Král, Zdeněk and Mayer, Jiří},
   article_location = {MALDEN, USA},
   article_number = {2},
   doi = {http://dx.doi.org/10.1002/hon.2974},
   keywords = {anti-SARS-CoV-2 monoclonal neutralizing antibodies; bamlanivimab; casirivimab; COVID-19; hematological malignancy; imdevimab; SARS-CoV-2},
   language = {eng},
   issn = {0278-0232},
   journal = {Hematological Oncology},
   title = {Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/hon.2974},
   volume = {40},
   year = {2022}
}

TY  - JOUR
ID  - 1853633
AU  - Weinbergerová, Barbora - Demel, Ivo - Visek, Benjamin - Valka, Jan - Cernan, Martin - Jindra, Pavel - Novak, Jan - Stejskal, Lukas - Kovácsová, Flóra - Kabut, Tomáš - Szotkowski, Tomas - Hajek, Roman - Zak, Pavel - Cetkovsky, Petr - Král, Zdeněk - Mayer, Jiří
PY  - 2022
TI  - Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience
JF  - Hematological Oncology
VL  - 40
IS  - 2
SP  - 280-286
EP  - 280-286
PB  - WILEY-BLACKWELL
SN  - 02780232
KW  - anti-SARS-CoV-2 monoclonal neutralizing antibodies
KW  - bamlanivimab
KW  - casirivimab
KW  - COVID-19
KW  - hematological malignancy
KW  - imdevimab
KW  - SARS-CoV-2
UR  - https://onlinelibrary.wiley.com/doi/10.1002/hon.2974
N2  - COVID-19 significantly impairs survival rates among hematological patients when compared to the general population. Our prospective multicentre project analyzed early administration of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies (NmAbs) - bamlanivimab (72%) and casirivimab/imdevimab (28%) - efficacy among hematological patients with early-stage COVID-19. Mortality rate was compared to a control cohort of 575 SARS-CoV-2 positive hematological patients untreated with any specific anti-COVID-19 therapy. 88 hematological patients with lymphomas, acute leukemias, and myeloma as their most frequent underlying diagnoses (72%) were evaluated with a 97 days median follow-up after NmAb administration. One third of patients (32%) were treated with an anti-CD20 monoclonal antibody before COVID-19 diagnosis. Median time between first COVID-19 symptom and NmAb administration was 2 days. When administering NmAb, 29%, 57%, 11%, 2%, and 1% of our patients had asymptomatic, mild, moderate, severe, and critical degrees of COVID-19, respectively. 80% of baseline asymptomatic patients remained asymptomatic following NmAb administration. Median duration of COVID-19 symptoms after NmAb administration was 2.5 days. Progression to severe/critical COVID-19 occurred among a total of 17% (15/88) of our cases and numerically higher with bamlanivimab versus casirivimab/imdevimab (21% vs. 8%; p = 0.215), and myelomas (29%), lymphomas (17%) and acute leukemias (18%), respectively. During final follow-up, nine deaths (10%) were recorded - all after bamlanivimab (p = 0.056) with 8% attributed to COVID-19. Regarding "remdesivir/convalescent plasma naive" patients, COVID-19 mortality rates were significantly lower in our NmAbs treated cohort compared to the control cohort of untreated SARS-CoV-2 positive hematological patients (6% vs. 16%, p = 0.020), respectively. Our study validated the safety and efficacy of NmAbs early use among hematological patients with newly diagnosed early-stage COVID-19 in terms of alleviating infection course and decreasing mortality. Results confirmed a more positive effect of a casirivimab/imdevimab combination versus bamlanivimab monotherapy.
ER  -

WEINBERGEROVÁ, Barbora, Ivo DEMEL, Benjamin VISEK, Jan VALKA, Martin CERNAN, Pavel JINDRA, Jan NOVAK, Lukas STEJSKAL, Flóra KOVÁCSOVÁ, Tomáš KABUT, Tomas SZOTKOWSKI, Roman HAJEK, Pavel ZAK, Petr CETKOVSKY, Zdeněk KRÁL a Jiří MAYER. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience. \textit{Hematological Oncology}. MALDEN, USA: WILEY-BLACKWELL, 2022, roč.~40, č.~2, s.~280-286. ISSN~0278-0232. Dostupné z: https://dx.doi.org/10.1002/hon.2974.

Podrobný výpis o publikaci